Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma

Maria S Asdourian; Tracey S Otto; Ted V Jacoby; Nishi Shah; Leah L Thompson; Steven M Blum; Kerry L Reynolds; Yevgeniy R Semenov; Donald P Lawrence; Ryan J Sullivan; Genevieve M Boland; Alexandra-Chloé Villani; Steven T Chen

doi:10.1016/j.jaad.2022.02.024

Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma

J Am Acad Dermatol. 2022 Nov;87(5):1147-1149. doi: 10.1016/j.jaad.2022.02.024. Epub 2022 Feb 19.

Authors

Affiliations

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii.
⁴ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Virginia Commonwealth University School of Medicine, Richmond, Virginia.
⁵ Harvard Medical School, Boston, Massachusetts; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts.
⁶ Harvard Medical School, Boston, Massachusetts; Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
⁷ Harvard Medical School, Boston, Massachusetts; Department of Medicine, Center for Immunology and Inflammatory Diseases and Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts.
⁸ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: [email protected].

No abstract available

Keywords: cutaneous immune-related adverse events; dermatologic toxicities; immune checkpoint inhibitor; immune-related adverse events; immunotherapy; melanoma; serum LDH; tumor burden.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Immunotherapy / adverse effects
Ipilimumab / adverse effects
Lactate Dehydrogenases
Melanoma* / etiology

Substances

Immune Checkpoint Inhibitors
Ipilimumab
Lactate Dehydrogenases

Grants and funding

L30 CA264747/CA/NCI NIH HHS/United States